Can I read Enhancing effect of Labrafac Lipophile WL 1349 on oral bioavailability of hydroxysafflor yellow A in rats on EtoBox?

Enhancing effect of Labrafac Lipophile WL 1349 on oral bioavailability of hydroxysafflor yellow A in rats by Shujing Wang; Minjie Sun; Qineng Ping is a Pharmacology, Toxicology and Pharmaceutics article available to read on EtoBox.

What is Enhancing effect of Labrafac Lipophile WL 1349 on oral bioavailability of hydroxysafflor yellow A in rats about?

The objective of the present investigation was to clarify the mechanism by which Labrafac Lipophile WL 1349 (WL 1349) enhanced the oral bioavailability (BA) of hydroxysafflor yellow A (HSYA), the representative low permeable hydrophilic (biopharmaceutic classification system (BCS) Class III) drug. HSYA-phospholipid complex was prepared, and dissolved into WL 1349 with a certain surfactant to form a stable oil solution. Oral administration of HSYA aqueous solution at a dosage of 4.5 mg/kg resulted a low plasma HSYA concentration with C max and AUC 0-8 h values of 0.105 g/ml and 10.29 g min/ml, respectively. HSYA-phospholipid complex oil solution with the same administration and dosage increased the plasma HSYA concentration significantly with C max and AUC 0-8 h values of 2.063 g/ml and 381.145 g min/ml, respectively. The results showed that WL 1349 could improve oral absorption of HSYA remarkably. Bioavailability investigations were performed to show WL 1349 dosage independent from HSYA absorption within the dosage from 1 ml/kg to 9 ml/kg. The test of bile duct ligation in rats showed that the oil solution containing WL 1349 did not result in detectable plasma HSYA concentration, b

Who reads Enhancing effect of Labrafac Lipophile WL 1349 on oral bioavailability of hydroxysafflor yellow A in rats?

Author

Shujing Wang; Minjie Sun; Qineng Ping

Publisher

Elsevier Science; Elsevier ; Elsevier BV (ISSN 0378-5173)

Published

2008

Language

EN

Field

Pharmacology, Toxicology and Pharmaceutics (Life Sciences)